Skip to main content
← All peptides
SleepAwaiting Reclassification

DSIP (Delta Sleep-Inducing Peptide)

The riddle peptide that rebalances sleep

Injection, Nasal · 503A Compounding

Educational content. This page describes DSIP (Delta Sleep-Inducing Peptide) for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.

Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.

Primary Use
A 9-residue neuropeptide that promotes deep sleep and modulates the stress response.
Administration
injection, nasal
Typical Cycle
Determined by a licensed provider
Legal Status
Awaiting Reclassification
Find a Provider

Key Benefits

Sleep Normalization

In the only published human polysomnography trial, intravenous DSIP lengthened sleep, reduced interruptions, and slightly increased REM in chronic insomniacs, with no daytime sedation. The authors described its effect as normalizing sleep regulation rather than forcing sedation.[4][5]

Stress Resilience

Animal work suggests DSIP buffers the stress response, shifting corticosterone, beta-endorphin, and substance P toward a more resilient profile under emotional and physical stress.[7][3]

Central Analgesia

Centrally administered DSIP produced a potent, dose-dependent painkilling effect in rodents. The effect was reversed by naloxone and depended on descending noradrenergic pathways, pointing to an opioid- and norepinephrine-linked mechanism.[8][12]

Mitochondrial and Hypoxia Protection

In rat brain mitochondria, DSIP improved phosphorylating respiration and fully blocked the drop in respiratory activity caused by experimental hypoxia, a cellular form of stress protection.[6]

What is DSIP (Delta Sleep-Inducing Peptide)?

Delta sleep-inducing peptide (DSIP) is a naturally occurring nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was characterized in 1977 by Schoenenberger and Monnier, who isolated a sleep-promoting factor from the cerebral venous blood of rabbits whose brains had been electrically stimulated to produce delta-wave (deep) sleep. Transferring the dialysate induced delta sleep in recipient rabbits, and the active fraction was identified as this short peptide.

DSIP is one of the most studied yet least understood peptides in neuroscience. A 2006 review in the Journal of Neurochemistry called it a still unresolved riddle: despite decades of work, the gene that would encode DSIP, its precursor protein, and a specific DSIP receptor have never been definitively identified. That gap leaves real uncertainty about whether the peptide acts through a dedicated pathway or as a broad modulator, and it is one reason the human evidence base remains thin compared with the volume of animal research.

On the regulatory side, the FDA listed DSIP (under the name Emideltide) in the 503A Category 2 bulk substances grouping in September 2024, citing a lack of human safety data for the proposed routes of administration along with immunogenicity concerns. Category 2 status means most compounding pharmacies decline to prepare it and many physicians are hesitant to prescribe it while the agency completes its review. This is an enforcement-risk classification, not a finding that DSIP is unsafe or prohibited.

How Does It Work?

DSIP does not appear to act through a single, well-defined receptor, which is unusual for a peptide with such varied reported effects. Because no specific DSIP receptor has been cloned, its mechanism is best described as broad neuromodulation: it influences several neurotransmitter and neuropeptide systems at once rather than switching one pathway on or off.

For sleep, the human and animal data point to a normalizing rather than sedating action. In cats given DSIP into the cerebral ventricles, sleep latency fell and slow-wave sleep rose, while in chronic insomniacs intravenous DSIP improved sleep continuity and quality. The human study saw a brief arousing effect in the first hour after injection followed by sleep enhancement in the second hour, consistent with a regulatory rather than a knockout effect.

DSIP's other reported actions trace to its influence on the stress axis and on cellular energetics. Animal studies link it to shifts in corticosterone, beta-endorphin, and substance P that correlate with greater stress resistance, and to improved mitochondrial respiration that protects brain tissue during hypoxia. Its analgesic effect in rodents runs through descending noradrenergic pathways and is blocked by the opioid antagonist naloxone, tying pain relief to opioid and norepinephrine signaling rather than to direct sedation.

Mechanism of Action

DSIP behaves as a broad neuromodulator rather than a single-receptor drug. It normalizes sleep architecture toward more continuous, slow-wave-rich sleep, buffers the stress axis through corticosterone and endorphin shifts, produces opioid- and noradrenaline-linked central analgesia, and protects brain mitochondria during hypoxic stress. No dedicated DSIP gene or receptor has been identified, which is why its mechanism remains only partly defined.

DSIPGABAergic ModulationInhibitory toneCircadian PacemakerSleep-wake regulationHPA AxisStress hormone controlEndorphin SystemPain modulationMitochondrial ProtectionCellular respirationSlow-Wave SleepDeep restorativesleep architectureSleep RegulationReduced latency& REM enhancementStress ProtectionCorticosterone &substance P balancePain ReductionCentral analgesiceffectsCell SurvivalPreserved respiratoryfunction under stressMulti-System Sleep & Stress Recovery

Clinical Evidence

Synthetic DSIP in Chronic Human Insomnia

Open polysomnography study, intravenous DSIP 25 nmol/kg6 middle-aged chronic insomniacs

DSIP produced longer sleep duration, higher sleep quality, and fewer interruptions with slightly more REM and no daytime sedation. A brief arousing effect appeared in the first hour, followed by sleep enhancement that persisted up to six hours. The authors framed the result as a normalizing influence on sleep regulation. This small, uncontrolled study remains the principal human sleep evidence.

Schneider-Helmert D, Schoenenberger GA · Experientia, 37(9):913-7 (1981) · PubMed

DSIP for Alcohol and Opiate Withdrawal

Open (uncontrolled) inpatient trial, intravenous DSIP107 inpatients (47 alcohol, 60 opiate withdrawal)

Withdrawal signs and symptoms reportedly disappeared or improved markedly in roughly 87 percent of alcohol and 97 percent of opiate patients, though anxiety responded more slowly and opiate patients needed more injections. Tolerance was good apart from headache in a few patients. The open design and lack of a control group limit the strength of these conclusions.

Dick P, Costa C, Fayolle K, et al. · Eur Neurol, 23(5):364-71 (1984) · PubMed

DSIP Effects on Sleep in Cats

Controlled preclinical study, intracerebroventricular DSIP with EEGCats with implanted electrodes

DSIP significantly reduced sleep latency and increased total sleep and slow-wave sleep time, supporting a cross-species sleep-promoting effect when delivered directly to the brain.

Susic V, Masirevic G, Totic S · Brain Res, 414(2):262-70 (1987) · PubMed

Antinociception via Descending Noradrenergic Pathways

Preclinical mechanism study in rodentsMice (intracerebroventricular DSIP)

DSIP produced dose-dependent analgesia in tail-pinch and hot-plate tests. The effect was reversed by naloxone, absent in morphine-tolerant animals, and blocked by spinal alpha-adrenergic antagonists, identifying opioid receptors and descending noradrenergic systems as the mediators.

Nakamura A, Nakashima M, Sugao T, et al. · Eur J Pharmacol, 155(3):247-53 (1988) · PubMed

Dosing & Administration

start low, go slow

Subcutaneous Injection

Dosage
100-300 mcg
Frequency
Once daily, evening
Cycle
Determined by a licensed provider

Intravenous (research setting)

Dosage
25 nmol/kg in the published human sleep study
Frequency
Single or short-course administration
Cycle
Study-defined

Subcutaneous Injection: Commonly timed 30-60 minutes before intended sleep. Doses are illustrative of community practice, not validated by controlled human trials.

Intravenous (research setting): The route used in the human insomnia and withdrawal trials. Not a typical outpatient protocol; included here to reflect the actual clinical literature.

There is no validated DSIP dosing protocol. The human trials used intravenous administration in supervised settings, while community subcutaneous regimens are extrapolated rather than evidence-based. Any dose, route, and schedule should be determined by a licensed provider.

DSIP clears the bloodstream very quickly. In dogs the measured plasma half-life was about four minutes, with similarly rapid clearance in rats and a monkey, which complicates dosing and means the durable effects seen in studies are not explained by simple plasma persistence.

Because the peptide is fragile, careful handling matters: reconstituted DSIP should be kept cold, protected from repeated freeze-thaw cycles, and used within the supplier's stated window to preserve potency.

Side Effects & Safety

Common

  • Injection site irritation: Mild redness or discomfort at a subcutaneous injection site

Uncommon

  • Headache: The main adverse effect noted in the 107-patient withdrawal trial; generally mild and transient
  • Transient first-hour arousal: A brief alerting effect was observed before sleep enhancement in the human sleep study; may feel like delayed sleep onset
  • Vivid dreams: Anecdotally reported, plausibly related to the modest increase in REM sleep

Safety Profile

DSIP has been administered to humans in research settings since the late 1970s with a generally favorable short-term tolerability profile. In the largest human series, 107 withdrawal inpatients, the only adverse effect noted was headache in a few patients. The insomnia study reported improved sleep with no daytime sedation.

Controlled human safety data are limited, and almost all of the trials are small, open, and decades old. The FDA specifically cited a lack of human safety data for the proposed routes of administration, along with immunogenicity concerns, when it placed DSIP (Emideltide) in 503A Category 2 in September 2024.

Because DSIP influences endorphin and stress-hormone systems, theoretical interactions with opioids, sedatives, and other neuroactive medications cannot be ruled out. Anyone taking such medications should only consider DSIP under provider supervision.

Contraindications

  • Pregnancy and breastfeeding (no safety data)
  • Concurrent prescription sleep medications without medical supervision
  • Concurrent opioid therapy (DSIP modulates opioid and endorphin signaling)
  • Severe hepatic or renal impairment (clearance and metabolism not characterized in these populations)
  • Known hypersensitivity to peptide preparations or reconstitution excipients

Regulatory Status

Under Review (Category 2)

503A Compounding

The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.

Reclassification Pending

In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.

Regulatory Detail

Listed in Category 2 under the name Emideltide (DSIP). No human safety data for the proposed routes of administration. FDA cited immunogenicity concerns and lack of clinical justification. Not eligible for compounding.

FDA Action History

What do these terms mean?
503A compounding
Licensed pharmacies that prepare custom prescriptions for individual patients based on a physician's order. 503A is the section of the federal law that governs them.
503B outsourcing
FDA-registered facilities that compound in larger batches under stricter federal oversight (closer to a manufacturer than a pharmacy). Used mostly by hospitals and clinics.
Bulk drug substance
The active pharmaceutical ingredient a compounder starts with, before it's made into a finished medication.
Category 1
Interim bucket for bulk substances that have been nominated and don't appear to present significant safety risks. 503A pharmacies may compound them under FDA enforcement discretion while the agency continues its review. Not the same as FDA approval.
Category 2
Bulk substances the FDA has flagged for significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare them and many physicians hesitate to prescribe them.
PCAC
Pharmacy Compounding Advisory Committee. The FDA advisory committee that reviews nominated bulk substances and recommends whether they belong in Category 1, Category 2, or on the final 503A Bulks List.

Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.

Frequently Asked Questions

Research & References

  1. 1

    Kovalzon VM, Strekalova TV “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” J Neurochem, 97(2):303-9 (2006)

    PubMedDOI
  2. 2

    Pollard BJ, Pomfrett CJ “Delta sleep-inducing peptide.” Eur J Anaesthesiol, 18(7):419-22 (2001)

    PubMedDOI
  3. 3

    Graf MV, Kastin AJ “Delta-sleep-inducing peptide (DSIP): an update.” Peptides, 7(6):1165-87 (1986)

    PubMedDOI
  4. 4

    Schneider-Helmert D, Schoenenberger GA “The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.” Experientia, 37(9):913-7 (1981)

    PubMedDOI
  5. 5

    Susic V, Masirevic G, Totic S “The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat.” Brain Res, 414(2):262-70 (1987)

    PubMedDOI
  6. 6

    Khvatova EM, Samartzev VN, Zagoskin PP, et al. “Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia.” Peptides, 24(2):307-11 (2003)

    PubMedDOI
  7. 7

    Sudakov KV, Coghlan JP, Kotov AV, et al. “Delta-sleep-inducing peptide sequels in the mechanisms of resistance to emotional stress.” Ann N Y Acad Sci, 771:240-51 (1995)

    PubMedDOI
  8. 8

    Nakamura A, Nakashima M, Sugao T, et al. “Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP).” Eur J Pharmacol, 155(3):247-53 (1988)

    PubMedDOI
  9. 9

    Schoenenberger GA, Monnier M “Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.” Proc Natl Acad Sci U S A, 74(3):1282-6 (1977)

    PubMedDOI
  10. 10

    Dick P, Costa C, Fayolle K, et al. “DSIP in the treatment of withdrawal syndromes from alcohol and opiates.” Eur Neurol, 23(5):364-71 (1984)

    PubMedDOI
  11. 11

    Backmund M, Meyer K, Rothenhaeusler HB, Soyka M “Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial.” J Clin Psychopharmacol, 18(3):257-8 (1998)

    PubMedDOI
  12. 12

    Nakamura A, Sugao T, Yamaue K, et al. “Involvement of spinal noradrenergic system in the mechanism of an antinociceptive effect of delta-sleep-inducing peptide (DSIP).” Brain Res, 480(1-2):82-6 (1989)

    PubMedDOI
  13. 13

    Kato N, Honda Y, Ebihara S, et al. “Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs.” Neuroendocrinology, 39(1):39-44 (1984)

    PubMedDOI
  14. 14

    Popovich IG, Voitenkov BO, Anisimov VN, et al. “Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice.” Mech Ageing Dev, 124(6):721-31 (2003)

    PubMedDOI

Ready to explore DSIP (Delta Sleep-Inducing Peptide) therapy?

Looking into DSIP (Delta Sleep-Inducing Peptide)? Find a provider who knows this peptide and can walk you through your options.

Find a Provider